Application of pyrimidinedione compound as microsome prostaglandin E2 synthase inhibitor

A technology of synthase inhibitors and pyrimidine diketones, which is applied in the application field of pyrimidine diketones as microsomal prostaglandin E2 synthase inhibitors, can solve the side effects of cardiovascular diseases and other problems, and achieve less adverse reactions and high efficacy. good effect

Pending Publication Date: 2021-08-27
MACAU UNIV OF SCI & TECH
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] The purpose of this application is to provide a kind of pyrimidine diketone compound as microsomal prostaglandin E 2 The application of synthase inhibitors aims to solve the problem that some non-steroidal anti-inflammatory drugs in the prior art will produce side effects related to cardiovascular diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of pyrimidinedione compound as microsome prostaglandin E2 synthase inhibitor
  • Application of pyrimidinedione compound as microsome prostaglandin E2 synthase inhibitor
  • Application of pyrimidinedione compound as microsome prostaglandin E2 synthase inhibitor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0057] Cell Viability Assay

[0058] Experimental procedure

[0059] (1) A549 cell culture and treatment

[0060] A549 cell line was purchased from American Type Culture Collection (ATCC, Manassas, VA, USA).

[0061] The cell culture medium is RPMI 1640, and 10% fetal bovine serum (Gibco BRL Co, Grand Island, NY, USA) and 1% penicillin G (100ml / unit), streptomycin (100mg / ml) and L- Glutamine (2 mM) (GibcoBRL Co, Grand Island, NY, USA).

[0062] Cells at 37°C with 5% CO 2 Incubate in an environment; A549 cells were incubated at 1×10 5 seeded in 6-well plates and incubated for 24 hours.

[0063] (2) Isolation and culture of primary rat peritoneal macrophages

[0064] SD rats (body weight 180-280g) purchased from the University of Hong Kong were provided, and peritoneal macrophages (RPM) were isolated from the mice and cultured in Dulbecco's modified Eagle's medium (DMEM); wherein, the medium was supplemented with 10% Fetal bovine serum (Gibco BRL Co, Grand Island, NY, U...

Embodiment 2

[0071] CLOS versus PGE in cell-free ELISA assay 2 and mPGES-1 protein activity

[0072] Experimental procedure

[0073] (1) Preparation of mPGES-1 protein

[0074] A549 cells were treated with 1.6×10 6 The density is inoculated at 175cm 2 and incubated for 24 hours; then stimulated the cells with 1ng / mL IL-1β for 72 hours; collected the cells and washed them twice with PBS; centrifuged the collected cell pellet at 1000rpm for 5 minutes, then discarded the supernatant; Pre-cooled homogeneous buffer (0.1M potassium phosphate buffer pH7.4, 1mM phenylmethanesulfonyl fluoride, 60μg / mL soybean trypsin inhibitor, 1μg / mL leupeptin, 2.5mM GSH and 250mM sucrose) weight Suspended cell pellets were disrupted with a sonic oscillator. The suspension was collected and centrifuged at 10000g for 10 minutes. The supernatant was collected and centrifuged at 50000 rpm for 1.5 hours. After ultracentrifugation, the supernatant was discarded, the pellet was collected and resuspended in homo...

Embodiment 3

[0080] Affinity detection of mPGES-1 protein and compounds in a cell-free assay

[0081] Experimental procedure

[0082] Assays were performed using a FortéBio Octet Red instrument, and all assays were performed using 96-well plates (Greiner Bio-One, PN: 655209). All final reaction volumes were controlled at 200 μL / well. Biotinylated mPGES-1 protein was immobilized on SA tips. The assay steps include: baseline zeroing, compound binding, and dissociation. Analysis of protein and drug affinity results was performed by ForteìBio data analysis software. To measure the interaction between compound CLOS and mPGES-1 protein, seven concentrations of compound CLOS (3.13, 6.25, 12.5, 25, 50, 100 μΜ) were employed in this assay.

[0083] Result analysis

[0084] Since the results of Example 2 have shown that CLOS can simultaneously reduce PGE 2 and the protein activity of mPGES-1, so the molecular docking method was used in this study to test the binding ability of CLOS to mPGE...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the technical field of biological medicine, and provides an application of a pyrimidinedione compound as a microsome prostaglandin E2 synthase inhibitor. The microsome prostaglandin E2 synthase inhibitor is a pyrimidinedione compound, and the pyrimidinedione compound is 2-{[((3-chlorphenyl)methyl]sulfanyl}-5-(3, 4-dihydroxyphenyl)-3H, 4H, 5H, 6H, 7H, 8H-pyridyl[2, 3-d]pyrimidine-4, 7-dione (CLOS for short), and reflects anti-inflammatory activity by remarkably reducing generation of PGE2 and inhibiting activity of mPGES-1 protein and further regulating expression of the mPGES-1 protein to inhibit generation of the PGE2; meanwhile, the CLOS has no obvious influence on COX-1 and COX-2, so that the CLOS can be used for treating inflammation, does not cause side effects of cardiovascular diseases and has a good effect.

Description

technical field [0001] The application belongs to the technical field of biomedicine, and in particular relates to a pyrimidinedione compound as microsomal prostaglandin E 2 Use of synthase inhibitors. Background technique [0002] Inflammation is a complex biological defense response of basal tissue to external stimuli such as pathogens, cell damage, or other irritating substances, manifested as redness, swelling, heat, pain, and dysfunction. Inflammation can be infectious inflammation caused by infection, or non-infectious inflammation not caused by infection. Normally, inflammation is beneficial and is the body's automatic defense response, but sometimes, inflammation is also harmful. Excessive inflammation can cause damage to matrix tissues and organs, such as attacks on the body's own tissues, occurring in hyaline tissues inflammation etc. When it is more serious, it will induce multiple organ failure and death. Therefore, the verification of the transition needs to ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/519A61P29/00
CPCA61K31/519A61P29/00
Inventor 周华刘良姚小军罗进芳姚允达廖俊杰
Owner MACAU UNIV OF SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap